Halda Therapeutics

High-Level Overview

Halda Therapeutics is a clinical-stage biotechnology company developing RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) therapeutics, innovative bifunctional small molecules that employ a novel "hold and kill" mechanism to selectively target and destroy cancer cells by linking a tumor-specific protein with an essential effector protein, leading to cancer cell death.[1][2][3][5] The company serves patients with hard-to-treat cancers, such as metastatic castration-resistant prostate cancer (mCRPC), addressing resistance mechanisms that limit current precision oncology drugs; its lead candidate, HLD-0915, received FDA Fast Track designation in August 2025 and showed encouraging safety and anti-tumor activity in first-in-human trials by October 2025.[2][4] Halda demonstrated strong growth momentum as a venture-backed firm in New Haven, CT, culminating in its acquisition by Johnson & Johnson on November 17, 2025.[1][2][4]

Origin Story

Halda Therapeutics was founded by Dr. Craig Crews, a pioneer in protein degradation technologies who launched Arvinas, Inc. in 2013 to advance PROTAC-based drugs and later established Halda to develop RIPTAC therapeutics as a distinct heterobifunctional modality for cancer.[3] The name "Halda," meaning "to hold" in old Nordic languages, reflects its core mechanism of tightly regulated protein holding.[3] Key leaders include CEO Chris Schade, with over 20 years in biotech including leading Aprea Therapeutics through IPO; CSO Dr. Kat Kayser-Bricker, an early team member expert in small molecule cancer discovery; and CMO Dr. Eyal Attar, with clinical training from Dana-Farber and Brigham and Women’s.[3] Early traction built through platform innovation, advancing HLD-0915 into clinical trials and securing FDA Fast Track status.[2][4]

Core Differentiators

• Novel "Hold and Kill" Mechanism: RIPTAC therapeutics form a trimeric complex inducing neomorphic protein-protein interactions between a tumor-specific target (e.g., androgen receptor in prostate cancer) and an essential effector protein, abrogating vital cell functions without relying on enzymatic degradation or disease drivers, overcoming resistance bypasses common in PROTACs or inhibitors.[1][2][5]
• Broad Applicability to "Undruggable" Targets: Targets intracellular proteins regardless of enzymatic activity, expanding beyond standard precision oncology to resistant solid tumors and earlier therapy lines.[2][3][5]
• Clinical Validation and Momentum: Lead asset HLD-0915 achieved FDA Fast Track for mCRPC, positive Phase 1 data presented at AACR-NCI-EORTC 2025, and rapid acquisition by Johnson & Johnson, signaling strong efficacy and pharmacology.[2][4]
• Expert Leadership in Platform Innovation: Team with proven track record in bifunctional molecules, company-building, and oncology drug development.[3]

Role in the Broader Tech Landscape

Halda rides the wave of induced proximity modalities in biotech, evolving from PROTACs to RIPTACs as next-gen tools against cancer's adaptive resistance, a key market force in precision oncology where ~50% of targeted therapies fail due to bypass mechanisms.[2][5] Timing aligns with surging demand for oral, intracellular-targeting small molecules amid aging populations and rising solid tumor incidence; FDA Fast Track and plenary presentations underscore regulatory tailwinds.[2][4] By proving RIPTACs' potential against "undruggable" proteins, Halda influences the ecosystem, accelerating heterobifunctional drug pipelines from firms like Arvinas and paving ways for Johnson & Johnson's oncology expansion post-acquisition.[3][4]

Quick Take & Future Outlook

With its 2025 acquisition by Johnson & Johnson, Halda's RIPTAC platform will likely scale rapidly through J&J's resources, advancing HLD-0915 toward pivotal trials in mCRPC and expanding pipeline programs for other solid tumors.[4] Trends like AI-driven protein design and combination therapies with immunotherapies will shape RIPTACs' evolution, potentially disrupting resistance-prone markets. Halda's "hold and kill" innovation, now amplified globally, positions it to redefine precision cancer treatment, conquering adaptive tumors where others falter.[2][5]